The AmoyDx® Myeloid Blood Cancer Panel enables a comprehensive molecular genetic analysis for the qualitative detection of SNVs, InDels and fusions in 55 genes associated with myeloid leukemia on DNA and RNA.
The AmoyDx® Myeloid Blood Cancer Panel is a Next-Generation Sequencing-based assay for the detection of mutations (SNVs), insertions and deletions (InDels) as well as fusions in 55 genes on DNA and RNA from bone marrow aspirates. In total, 252 different gene fusions can be detected using this assay.
The focus of this assay is on the tumor entities AML and CML, but may be further suited to characterize other hematologic malignancies. The analysis of the sequence data can be performed locally using the AmoyDx® NGS Data Analysis System (ANDAS).
Please find a detailed description of the AmoyDx® Myeloid Blood Cancer Panel here
This product is for research use only (RUO)
Recently, a second ZytoDot ® 2C probe for detecting rearrangements of the NTRK genes has become available: the new ZytoDot ® 2C SPEC NTRK3 Break Apart Probe (C-3079-100). Together with the already existing ZytoDot ® 2C SPEC NTRK1 Break Apart Probe (C-3078-100), a large range of NTRK rearrangements can be covered now. Both probes are designed for the qualitative detection of NTRK3 and NTRK1 rearrangements in FFPE tissue using the ZytoDot ® 2C CISH implementation Kit.
As a manufacturer and distributor of in vitro diagnostics, our enterprise group with the companies Zytomed Systems GmbH and ZytoVision GmbH attaches great importance to the timely implementation of the requirements of the IVDR (Regulation (EU) 2017/746 of the European Parliament and of the Council of April 5th 2017 on in vitro diagnostic medical devices).